GREY:ATBPF - Post by User
Post by
Actuarialon Jan 07, 2021 8:57am
179 Views
Post# 32240640
Dr. Haut spearheaded AskBio’s recent $4 billion acquisition
Dr. Haut spearheaded AskBio’s recent $4 billion acquisition TORONTO — Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced the appointment of Dr. Don Haut to its Partnering Advisory Team.
“I am delighted to welcome another superstar to our Partnering Advisory Team,” remarked Dan Legault, Antibe’s CEO. “Don’s broad background and tremendous recent success will add new depth to our business development capability as our partnering activities accelerate in 2021.”
Most recently, Dr. Haut was Chief Business Officer of AskBio, a leading clinical stage developer of gene therapies and technologies. He led the firm’s business development activities, completing four transactions in 2020 before taking a leading role in AskBio’s $4 billion acquisition by Bayer AG. In a career spanning academic science, consulting, sales management, and business development, he has completed transactions exceeding $8 billion and been instrumental in multiple product launches. He has also served on the boards of several healthcare companies, including firms involved in joint replacement and repair.
Originally trained as a molecular biologist before joining McKinsey, Dr. Haut has since held senior business roles at 3M Company, Smith & Nephew, and The Medicines Company. More recently, he was Chief Business Officer of Histogenics and Sherlock Biosciences. He earned his PhD in Molecular Biology from the Medical School at the University of Missouri-Columbia and an MBA from Washington University’s Olin School of Business.
Dr. Haut commented, “Antibe’s platform promises a major advance in the treatment of pain and inflammation-based disease. This area is overdue for disruption and represents a massive commercial opportunity. I’m excited to put my shoulder to the wheel to help Antibe fully capture the value of its pipeline as it enters late-stage development.”